To include your compound in the COVID-19 Resource Center, submit it here.

Glenmark, Sanofi deal

Sanofi received rights to develop and commercialize Glenmark's autoimmune candidate GBR 500. The mAb against integrin

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE